TY - JOUR
T1 - Guidance on short-term management of atrial fibrillation in coronavirus disease 2019
AU - Rattanawong, Pattara
AU - Shen, Win-Kuang
AU - Masry, Hicham El
AU - Sorajja, Dan
AU - Srivathsan, Komandoor
AU - Valverde, Arturo
AU - Scott, Luis R.
N1 - Funding Information:
This research is partially supported by Mayo Clinic Cardiovascular Research
Publisher Copyright:
© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
PY - 2020/7/21
Y1 - 2020/7/21
N2 - Atrial fibrillation is a common clinical manifestation in hospitalized patients with coronavirus disease 2019 (COVID-19). Medications used to treat atrial fibrillation, such as antiarrhythmic drugs and anticoagulants, may have significant drug interactions with emerging COVID-19 treatments. Common unintended nontherapeutic target effects of COVID-19 treatment include potassium channel blockade, cytochrome P 450 isoenzyme inhibition or activation, and P-glycoprotein inhibition. Drug-drug interactions with antiarrhythmic drugs and anticoagulants in these patients may lead to significant bradycardia, ventricular arrhythmias, or severe bleeding. It is important for clinicians to be aware of these interactions, drug metabolism changes, and clinical consequences when choosing antiarrhythmic drugs and anticoagulants for COVID-19 patients with atrial fibrillation. The objective of this review is to provide a practical guide for clinicians who are managing COVID-19 patients with concomitant atrial fibrillation.
AB - Atrial fibrillation is a common clinical manifestation in hospitalized patients with coronavirus disease 2019 (COVID-19). Medications used to treat atrial fibrillation, such as antiarrhythmic drugs and anticoagulants, may have significant drug interactions with emerging COVID-19 treatments. Common unintended nontherapeutic target effects of COVID-19 treatment include potassium channel blockade, cytochrome P 450 isoenzyme inhibition or activation, and P-glycoprotein inhibition. Drug-drug interactions with antiarrhythmic drugs and anticoagulants in these patients may lead to significant bradycardia, ventricular arrhythmias, or severe bleeding. It is important for clinicians to be aware of these interactions, drug metabolism changes, and clinical consequences when choosing antiarrhythmic drugs and anticoagulants for COVID-19 patients with atrial fibrillation. The objective of this review is to provide a practical guide for clinicians who are managing COVID-19 patients with concomitant atrial fibrillation.
KW - Antiarrhythmic drug
KW - Atrial fibrillation
KW - COVID-19
UR - http://www.scopus.com/inward/record.url?scp=85088493728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088493728&partnerID=8YFLogxK
U2 - 10.1161/JAHA.120.017529
DO - 10.1161/JAHA.120.017529
M3 - Review article
C2 - 32515253
AN - SCOPUS:85088493728
VL - 9
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
SN - 2047-9980
IS - 14
M1 - e017529
ER -